Japan Pharma Archives | Report Store

Astellas Company Analysis

Analysis of Astellas’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.

September 19, 2018

Find out more

Shire Company Analysis

$3,000.00

PharmaVitae explores Shire’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

August 30, 2018

Find out more

Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.

July 2, 2018

Find out more

Mitsubishi Tanabe Company Analysis

$3,000.00

Updated analysis and forecasts based on Q1 2017 company-reported sales.

October 6, 2017

Find out more

Takeda

$3,000.00

Analysis of Takeda’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2014–24.

September 19, 2017

Find out more

Dainippon Sumitomo Company Analysis

$3,000.00

Analysis of Dainippon Sumitomo’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.

September 19, 2017

Find out more

Shionogi Company Analysis

$3,000.00

Updated analysis and forecasts based on 2016 company-reported sales.

Pharmavitae Analytics explores Shionogi’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

August 31, 2017

Find out more

Otsuka Company Analysis

$3,000.00

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

August 28, 2017

Find out more

Eisai Company Analysis

$3,000.00

Pharmavitae Analytics explores Eisai’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

August 28, 2017

Find out more

Daiichi Sankyo Company Analysis

$3,000.00

PharmaVitae explores Daiichi Sankyo’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

August 22, 2017

Find out more

Shinogi

$3,000.00

Analysis of Shionogi’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.

September 28, 2016

Find out more

Japan Pharma Outlook

$3,000.00

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.

September 28, 2016

Find out more